Literature DB >> 25667909

Axillary lymph node management in breast cancer with positive sentinel lymph node biopsy.

Ioannis A Voutsadakis1, Silvana Spadafora1.   

Abstract

The surgical treatment of localized breast cancer has become progressively less aggressive over the years. The management of the axillary lymph nodes has been modified by the introduction of sentinel lymph node biopsy. Axillary dissection can be avoided in patients with sentinel lymph node negative biopsies. Based on randomized trials data, it has been proposed that no lymph node dissection should be carried out even in certain patients with sentinel lymph node positive biopsies. This commentary discusses the basis of such recommendations and cautions against a general omission of lymph node dissection in breast cancer patients with positive sentinel lymph node biopsies. Instead, an individualized approach based on axillary tumor burden and biology of the cancer should be considered.

Entities:  

Keywords:  Axillary lymph node dissection; Axillary recurrence; Breast cancer; Macro-metastatic; Micro-metastatic; Node positive; Tumor sub-types

Year:  2015        PMID: 25667909      PMCID: PMC4318745          DOI: 10.5306/wjco.v6.i1.1

Source DB:  PubMed          Journal:  World J Clin Oncol        ISSN: 2218-4333


  25 in total

1.  Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer.

Authors:  G Cserni; D Gregori; F Merletti; A Sapino; M P Mano; A Ponti; S Sandrucci; B Baltás; G Bussolati
Journal:  Br J Surg       Date:  2004-10       Impact factor: 6.939

2.  Phase III randomized equivalence trial of early breast cancer treatments with or without axillary clearance in post-menopausal patients results after 5 years of follow-up.

Authors:  A Avril; G Le Bouëdec; G Lorimier; J M Classe; C Tunon-de-Lara; S Giard; G MacGrogan; M Debled; S Mathoulin-Pélissier; L Mauriac
Journal:  Eur J Surg Oncol       Date:  2011-06-12       Impact factor: 4.424

Review 3.  Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis.

Authors:  Tracey DiSipio; Sheree Rye; Beth Newman; Sandi Hayes
Journal:  Lancet Oncol       Date:  2013-03-27       Impact factor: 41.316

4.  A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: results after 5 years of follow-up.

Authors:  Gabriele Martelli; Patrizia Boracchi; Michaela De Palo; Silvana Pilotti; Saro Oriana; Roberto Zucali; Maria Grazia Daidone; Giuseppe De Palo
Journal:  Ann Surg       Date:  2005-07       Impact factor: 12.969

Review 5.  Evolution of axillary nodal staging in breast cancer: clinical implications of the ACOSOG Z0011 trial.

Authors:  Miraj Shah-Khan; Judy C Boughey
Journal:  Cancer Control       Date:  2012-10       Impact factor: 3.302

6.  Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.

Authors:  Viviana Galimberti; Bernard F Cole; Stefano Zurrida; Giuseppe Viale; Alberto Luini; Paolo Veronesi; Paola Baratella; Camelia Chifu; Manuela Sargenti; Mattia Intra; Oreste Gentilini; Mauro G Mastropasqua; Giovanni Mazzarol; Samuele Massarut; Jean-Rémi Garbay; Janez Zgajnar; Hanne Galatius; Angelo Recalcati; David Littlejohn; Monika Bamert; Marco Colleoni; Karen N Price; Meredith M Regan; Aron Goldhirsch; Alan S Coates; Richard D Gelber; Umberto Veronesi
Journal:  Lancet Oncol       Date:  2013-03-11       Impact factor: 41.316

7.  Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011.

Authors:  Anthony Lucci; Linda Mackie McCall; Peter D Beitsch; Patrick W Whitworth; Douglas S Reintgen; Peter W Blumencranz; A Marilyn Leitch; Sukumal Saha; Kelly K Hunt; Armando E Giuliano
Journal:  J Clin Oncol       Date:  2007-05-07       Impact factor: 44.544

Review 8.  Management of the clinically node-negative axilla: what have we learned from the clinical trials?

Authors:  Melissa L Pilewskie; Monica Morrow
Journal:  Oncology (Williston Park)       Date:  2014-05       Impact factor: 2.990

9.  Micrometastases or isolated tumor cells and the outcome of breast cancer.

Authors:  Maaike de Boer; Carolien H M van Deurzen; Jos A A M van Dijck; George F Borm; Paul J van Diest; Eddy M M Adang; Johan W R Nortier; Emiel J T Rutgers; Caroline Seynaeve; Marian B E Menke-Pluymers; Peter Bult; Vivianne C G Tjan-Heijnen
Journal:  N Engl J Med       Date:  2009-08-13       Impact factor: 91.245

Review 10.  Intratumoral heterogeneity, its contribution to therapy resistance and methodological caveats to assessment.

Authors:  Mirjam Renovanz; Ella L Kim
Journal:  Front Oncol       Date:  2014-06-10       Impact factor: 6.244

View more
  3 in total

Review 1.  Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives.

Authors:  Meagan B Myers
Journal:  Pharmgenomics Pers Med       Date:  2016-01-22

2.  Intravital imaging reveals systemic ezrin inhibition impedes cancer cell migration and lymph node metastasis in breast cancer.

Authors:  Abdi Ghaffari; Victoria Hoskin; Gulisa Turashvili; Sonal Varma; Jeff Mewburn; Graeme Mullins; Peter A Greer; Friedemann Kiefer; Andrew G Day; Yolanda Madarnas; Sandip SenGupta; Bruce E Elliott
Journal:  Breast Cancer Res       Date:  2019-01-24       Impact factor: 6.466

3.  The Diagnostic Performance of Machine Learning-Based Radiomics of DCE-MRI in Predicting Axillary Lymph Node Metastasis in Breast Cancer: A Meta-Analysis.

Authors:  Jing Zhang; Longchao Li; Xia Zhe; Min Tang; Xiaoling Zhang; Xiaoyan Lei; Li Zhang
Journal:  Front Oncol       Date:  2022-02-04       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.